| Ytd | -64.42% | |
| 1y | -36.25% |
| Open | 0.46 | Prev Close | 0.45 | Low | 0.46 | High | 0.47 | Mkt Cap | 3.38M |
| Vol | 3.05K | Avg Vol | 805.22K | EPS | -1.60 | P/E | -0.28 | Forward P/E | -3.75 |
| Beta | 0.29 | Short Ratio | 0.32 | Inst. Own | 2.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-16 | 50-d Avg | 0.60 | 200-d Avg | 0.78 | 1yr Est | 2.00 |
KTTA News
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK In
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK In
KTTA, NTRS, YEXT, AEHR and STT have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 20
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Bu
-- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and lo
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145326
Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.12) per share which beat the an
HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Bu
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-
